1. Home
  2. PEG vs ALNY Comparison

PEG vs ALNY Comparison

Compare PEG & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Public Service Enterprise Group Incorporated

PEG

Public Service Enterprise Group Incorporated

HOLD

Current Price

$83.19

Market Cap

42.6B

Sector

Utilities

ML Signal

HOLD

Logo Alnylam Pharmaceuticals Inc.

ALNY

Alnylam Pharmaceuticals Inc.

HOLD

Current Price

$322.18

Market Cap

42.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PEG
ALNY
Founded
1903
2002
Country
United States
United States
Employees
N/A
115
Industry
Power Generation
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
42.6B
42.1B
IPO Year
1994
2004

Fundamental Metrics

Financial Performance
Metric
PEG
ALNY
Price
$83.19
$322.18
Analyst Decision
Buy
Strong Buy
Analyst Count
11
28
Target Price
$92.32
$471.93
AVG Volume (30 Days)
2.3M
1.1M
Earning Date
04-29-2026
04-30-2026
Dividend Yield
3.19%
N/A
EPS Growth
19.21
206.88
EPS
4.22
2.33
Revenue
$12,168,000,000.00
$1,037,418,000.00
Revenue This Year
$4.69
$52.99
Revenue Next Year
$4.22
$31.77
P/E Ratio
$19.89
$137.81
Revenue Growth
18.25
22.88
52 Week Low
$76.74
$225.84
52 Week High
$91.26
$495.55

Technical Indicators

Market Signals
Indicator
PEG
ALNY
Relative Strength Index (RSI) 54.49 49.11
Support Level $80.11 $302.52
Resistance Level $83.97 $330.33
Average True Range (ATR) 1.34 10.91
MACD 0.30 1.16
Stochastic Oscillator 75.96 62.72

Price Performance

Historical Comparison
PEG
ALNY

About PEG Public Service Enterprise Group Incorporated

Public Service Enterprise Group is the holding company for a regulated utility (PSE&G) and PSEG Power, which owns all or a share of three nuclear plans and clean energy projects. PSE&G provides regulated gas and electricity delivery services in New Jersey to a combined 4.3 million customers. Public Service Enterprise Group also operates the Long Island Power Authority system. In 2022, the company sold its gas and oil power plants in the mid-Atlantic, New York, and the Northeast.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway in cells that enables sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Share on Social Networks: